Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

Completed · Phase 1

Conditions studied: Brain Neoplasms

In brief

Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.

Key facts

Study ID

NCT00393965

Run by

Myrexis Inc.

People needed

18

Starts

2005-12-01

Expected to finish

2008-02-01

Last updated by the study team

2008-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Refractory Brain Metastases
• At least 1 measurable intracranial lesion as defined by RECIST
• ECOG less than or equal to 1
• Adequate hematology/organ function
• No baseline peripheral or central neuropathy above grade 1

You may not qualify if…

• Hypersensitivity to Cremophor EL
• Pregnant or Lactating
• Spinal Cord Compression
• Pre-existing dementia/cognitive disfunction
• Require Neupogen or Neulasta to Maintain Neutrophil Count
• Have Primary Brain Cancer
• Have History of Ischemic Heart Disease
• Have Diabetes

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.